-
‘We applaud CMS’: Two more rheumatology drugs bound for Medicare price negotiation
29 Jan 2025 14:43 GMT
… Teva Pharmaceuticals);
enzalutamide (Xtandi; Astellas, Pfizer);
fluticasone furoate; umeclidinium … D spending on prescription drugs.”
Medicare Drug Price Negotiation Program: Selected … the next fifteen drugs selected for Medicare drug price negotiation. …
-
Beta Lactam And Beta Lactamase Inhibitors Market To Grow By USD 8.4 Billion (2025-2029), Driven By Novel Drug Development, AI-Powered Market Evolution - Technavio
29 Jan 2025 05:28 GMT
… Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Inc., … and Monobactam are key drug classes. However, antibiotic resistance … efficacy of these new drugs, particularly in the … Segmentation
Route Of Administration
Drug Class
Cephalosporins
Penicillins
…
-
Explainer-Trump tariffs on chips and drugs would hit U.S. allies in Asia
28 Jan 2025 10:30 GMT
… major drugmakers such as Takeda, Astellas, Daiichi Sankyo and Eisai, … its Alzheimer's disease drug Leqembi.
Story Continues For … last financial year, while for Astellas it accounted for 41%. … imports. In a statement, Astellas said it was always preparing …
-
Antibody Drug Conjugates Market To Surpass US$ 34 Billion By 2032 | Product, Application, Technology, End-User
27 Jan 2025 12:08 GMT
… ) is Changing the Antibody Drug Conjugates Market?
Artificial Intelligence … combining antibodies with cytotoxic drugs requires advanced manufacturing capabilities …
• AstraZeneca
• Gilead Sciences, Inc.
• Astellas Pharma, Inc.
• Seagen, Inc.
• Daiichi …
-
What will happen to Medicare drug pricing negotiations under Trump?
24 Jan 2025 22:21 GMT
… new round of Medicare drug pricing negotiations to parse … the next 15 prescription drugs subject to Medicare negotiations late … ’s Ozempic and Wegovy, Astellas Pharma’s Xtandi, and … to patients, Ramachandran believes drug pricing reform should continue to …
-
Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More
24 Jan 2025 06:25 GMT
… developing KRAS G12D-targeting drugs, such as Revolution Medicines … Mirati Therapeutics. But Astellas envisions potentially bringing its … of excitement.”
Astellas’s newest cancer drug is Vyloy, … developed drug is a monoclonal antibody. The Astellas pipeline …
-
Teva, Astellas plan to participate in IRA drug price negotiations
23 Jan 2025 22:18 GMT
-
Antibody Drug Conjugate Market to Register Incremental Growth at a CAGR of ~14.37% by 2030 | DelveInsight
23 Jan 2025 10:21 GMT
… with the potency of cytotoxic drugs, ADCs offer a precision medicine … Therapeutics., Astellas Pharma Inc., AstraZeneca, ImmunoGen Inc. and others.
Antibody Drug Conjugate …
-
Saudi Arabia Pharmaceutical Drugs Market Is Booming Worldwide 2025-2032: Julphar, Biocon Limited, BeiGene, Pfizer Inc.
23 Jan 2025 09:24 GMT
… .
◘ AstraZeneca Plc
◘ Baxter International Inc.
◘ Astellas Pharma
◘ Life Care Group of …
Market Segmentation:
By Drug Type: Generic Drugs, Branded Drugs
By Product Type: Prescription …
-
Antibody Drug Conjugates Market Report 2025-2035: ADCs - Pioneering the Future of Precision Cancer Therapy - ResearchAndMarkets.com
20 Jan 2025 15:40 GMT
… . Hoffmann-La Roche, Astellas Pharma Inc., GSK, and … .
AstraZeneca
Gilead Sciences
Astellas Pharma
Daiichi Sankyo Company … Antibody-Drug Conjugates
Presence of Strong Emerging Pipeline Drugs
… Pfizer
AstraZeneca
Gilead Sciences
Astellas Pharma
Daiichi Sankyo
GSK …
About
© 1995-2025